Urotensin-II-Targeted Liposomes as a New Drug Delivery System towards Prostate and Colon Cancer Cells.
Journal
Journal of oncology
ISSN: 1687-8450
Titre abrégé: J Oncol
Pays: Egypt
ID NLM: 101496537
Informations de publication
Date de publication:
2019
2019
Historique:
received:
27
06
2019
accepted:
26
10
2019
entrez:
14
1
2020
pubmed:
14
1
2020
medline:
14
1
2020
Statut:
epublish
Résumé
Urotensin-II (UT-II) and its receptor (UTR) are involved in the occurrence of different epithelial cancers. In particular, UTR was found overexpressed on colon, bladder, and prostate cancer cells. The conjugation of ligands, able to specifically bind receptors that are overexpressed on cancer cells, to liposome surface represents an efficient active targeting strategy to enhance selectivity and efficiency of drug delivery systems. The aim of this study was to develop liposomes conjugated with UT-II (LipoUT) for efficient targeting of cancer cells that overexpress UTR. The liposomes had a mean diameter between 150 nm and 160 nm with a narrow size distribution (PI ≤ 0.1) and a doxo encapsulation efficiency of 96%. Moreover, the conjugation of UT-II to liposomes weakly reduced the zeta potential. We evaluated UTR expression on prostate (DU145, PC3, and LNCaP) and colon (WIDR and LoVo) cancer cells by FACS and western blotting analysis. UTR protein was expressed in all the tested cell lines; the level of expression was higher in WIDR, PC3, and LNCaP cells compared with LoVo and DU145. MTT cell viability assay showed that LipoUT-doxo was more active than Lipo-doxo on the growth inhibition of cells that overexpressed UTR (PC3, LNCaP, and WIDR) while in LoVo and DU145 cell lines, the activity was similar to or lower than that one of Lipo-doxo, respectively. Moreover, we found that cell uptake of Bodipy-labeled liposomes in PC3 and DU145 was higher for LipoUT than the not-armed counterparts but at higher extent in UTR overexpressing PC3 cells (about 2-fold higher), as evaluated by both confocal and FACS. In conclusion, the encapsulation of doxo in UT-II-targeted liposomes potentiated its delivery in UTR-overexpressing cells and could represent a new tool for the targeting of prostate and colon cancer.
Identifiants
pubmed: 31929800
doi: 10.1155/2019/9293560
pmc: PMC6942863
doi:
Types de publication
Journal Article
Langues
eng
Pagination
9293560Informations de copyright
Copyright © 2019 Silvia Zappavigna et al.
Déclaration de conflit d'intérêts
The authors declare that they have no conflicts of interest.
Références
Ann Endocrinol (Paris). 2019 Jun;80(3):149-152
pubmed: 31064661
Oncotarget. 2016 Apr 12;7(15):20753-72
pubmed: 26980746
Cell Mol Biol Lett. 2002;7(2):217-9
pubmed: 12097921
J Control Release. 2001 Jul 6;74(1-3):95-113
pubmed: 11489487
Circ Res. 2005 Sep 30;97(7):707-15
pubmed: 16141412
Oncotarget. 2015 Oct 13;6(31):31461-78
pubmed: 26372812
Vasc Health Risk Manag. 2010 Sep 07;6:723-34
pubmed: 20859543
Peptides. 2001 Jul;22(7):1175-9
pubmed: 11445248
ACS Nano. 2009 Jan 27;3(1):16-20
pubmed: 19206243
Eur J Clin Invest. 2014;44(3):285-94
pubmed: 24372535
Curr Drug Metab. 2012 Jan;13(1):4-21
pubmed: 22292808
J Chemother. 2004 Nov;16 Suppl 4:94-7
pubmed: 15688621
AAPS PharmSciTech. 2016 Dec;17(6):1298-1311
pubmed: 26689406
J Control Release. 2011 Feb 28;150(1):2-22
pubmed: 21095210
Endocr Relat Cancer. 2014 Jan 21;21(1):R67-83
pubmed: 24292602
Mol Neurobiol. 2017 Sep;54(7):4879-4895
pubmed: 27514754
J Med Chem. 2008 Nov 13;51(21):6639-41
pubmed: 18839938
Clin Pharmacokinet. 2003;42(5):419-36
pubmed: 12739982
ChemMedChem. 2016 Aug 19;11(16):1856-64
pubmed: 27061352
Curr Cancer Drug Targets. 2012 Mar;12(3):186-96
pubmed: 22268384
J Med Chem. 2019 Feb 14;62(3):1455-1467
pubmed: 30615452
Br J Pharmacol. 2006 Jan;147(1):92-100
pubmed: 16273120
J Exp Clin Cancer Res. 2014 Jun 03;33:48
pubmed: 24893613
Eur J Pharm Biopharm. 2013 Nov;85(3 Pt A):373-80
pubmed: 23791684
Drugs. 1997;54 Suppl 4:15-21
pubmed: 9361957
J Biol Chem. 1982 Jan 10;257(1):286-8
pubmed: 7053372
Int J Pharm. 2007 Feb 1;329(1-2):94-102
pubmed: 16997518
J Cell Biochem. 2011 Jan;112(1):341-53
pubmed: 21080343
Talanta. 2006 Jan 15;68(3):693-9
pubmed: 18970377
J Med Chem. 2014 Jul 24;57(14):5965-74
pubmed: 24992374
Curr Med Chem. 2004 Apr;11(8):969-79
pubmed: 15078159
J Med Chem. 2016 May 26;59(10):4740-52
pubmed: 27140209
Curr Cancer Drug Targets. 2017;17(2):109-121
pubmed: 27338741
Biosci Rep. 1998 Apr;18(2):69-78
pubmed: 9743475
J Pept Sci. 2015 May;21(5):392-9
pubmed: 25694247
Proc Natl Acad Sci U S A. 1991 Dec 15;88(24):11460-4
pubmed: 1763060
Int J Nanomedicine. 2012;7:4391-408
pubmed: 22927757
Endocr Relat Cancer. 2017 Jan;24(1):R1-R12
pubmed: 27799362
Expert Opin Drug Deliv. 2008 Jan;5(1):25-44
pubmed: 18095927
Biomed Res Int. 2014;2014:765426
pubmed: 24795894
Plant Physiol. 1980 Feb;65(2):245-8
pubmed: 16661168
Adv Drug Deliv Rev. 2004 Apr 29;56(8):1177-92
pubmed: 15094214
Prev Med. 2003 Dec;37(6 Pt 1):627-34
pubmed: 14636796
Trends Cardiovasc Med. 2000 Aug;10(6):229-37
pubmed: 11282300
Curr Drug Metab. 2012 Jan;13(1):61-9
pubmed: 22292810
J Amino Acids. 2013;2013:979016
pubmed: 23533711
Adv Enzyme Regul. 2001;41:189-207
pubmed: 11384745
Drug Deliv. 2016 May;23(4):1171-83
pubmed: 26036724
Endocrine. 2017 Aug;57(2):214-219
pubmed: 27481363
Biochim Biophys Acta. 2006 Oct;1758(10):1633-40
pubmed: 16887094
J Vasc Res. 2013;50(2):109-23
pubmed: 23172421